Liposomes are now considered the most commonly used nanocarriers for various potentially
active hydrophobic and hydrophilic molecules due to their high biocompatibility …

The first closed bilayer phospholipid systems, called liposomes, were described in 1965 and
soon were proposed as drug delivery systems. The pioneering work of countless liposome …

Developing innovative delivery strategies remains an ongoing task to improve both efficacy
and safety of drug‐based therapy. Nanomedicine is now a promising field of investigation …

Liposomes have gained increased attention as systemic drug delivery vehicles following
recent regulatory approvals of several vesicle-formulated drugs. These products have …

Sažetak Liposomes have been widely investigated since 1970 as drug carriers for improving
the delivery of therapeutic agents to specific sites in the body. As a result, numerous …

Liposomes represent a widely varied and malleable class of drug carriers generally
characterized by the presence of one or more amphiphile bilayers enclosing an interior …

The liposome, a closed phospholipid bilayered vesicular system, has received considerable
attention as a pharmaceutical carrier of great potential over the past 30 years. The ability of …

Liposomes were the first nanoscale drug to be approved for clinical use in 1995. Since then,
the technology has grown considerably, and pioneering recent work in liposome-based …

The liposomes have continued to be well-recognized as an important nano-sized drug
delivery system with attractive properties, such a characteristic bilayer structure assembling …

Liposomes, the most widely studied nano-drug carriers in drug delivery, are sphere-shaped
vesicles consisting of one or more phospholipid bilayers. Compared with traditional drug …